Adam Bostick, MD
Pulmonary Disease · Myrtle Beach, SCNPI 1740496041
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 140 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 20.9% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for pulmonary disease clinicians in SC, where the typical reported total is $2,769.
Across 140 payments — averaging $19.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$586
- AstraZeneca$238
- Sanofi$233
- Boehringer Ingelheim$177
- Insmed, Inc.$177
- Regeneron Healthcare Solutions, Inc.$160
- plus $1K from 25 others
Across 6 payments — averaging $5925.82 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$36K
What the payments were for
- Food & beverage$2,77999%
- Education$181%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 28 | $586 |
| AstraZeneca(2 entities) | 14 | $238 |
| Sanofi | 9 | $233 |
| Boehringer Ingelheim | 15 | $177 |
| Insmed, Inc. | 7 | $177 |
| Regeneron Healthcare Solutions, Inc. | 5 | $160 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $136 |
| Abbott | 5 | $108 |
| Amgen | 5 | $92 |
| Actelion Pharmaceuticals US, Inc. | 3 | $89 |
| AbbVie(2 entities) | 5 | $84 |
| Sunovion Pharmaceuticals Inc. | 6 | $74 |
| Merck | 4 | $62 |
| Grifols USA, LLC | 3 | $62 |
| Genentech USA, Inc. | 3 | $53 |
| Vital Connect, Inc | 1 | $52 |
| Electromed, Inc. | 3 | $49 |
| Pfizer | 2 | $49 |
| Philips North America LLC | 2 | $47 |
| Verona Pharma, Inc. | 2 | $39 |
| Bayer | 2 | $36 |
| Novartis | 2 | $33 |
| Mallinckrodt Hospital Products Inc. | 1 | $29 |
| United Therapeutics Corporation | 1 | $25 |
| Fisher & Paykel Healthcare Inc | 1 | $25 |
| Viatris Specialty LLC | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Nabriva Therapeutics, PLC | 1 | $14 |
| Circassia Inc. | 1 | $14 |
| Biomerieux Inc | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NUCALA$113
How this compares
$2,797 in reported general payments places this provider in the 50th percentile of 192 pulmonary disease providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 63 | $917,389 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 160 | $137,963 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 73 | $69,256 |
| Breo ElliptaFluticasone/Vilanterol | 73 | $42,837 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 70 | $34,177 |
| Spiriva HandihalerTiotropium Bromide | 30 | $28,337 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 35 | $22,237 |
| Spiriva RespimatTiotropium Bromide | 13 | $15,023 |
| SymbicortBudesonide/Formoterol Fumarate | 30 | $10,116 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 262 | $8,204 |
| Wixela InhubFluticasone Propion/Salmeterol | 43 | $8,061 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 28 | $5,262 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 14 | $2,460 |
| Azithromycin | 101 | $1,617 |
| Pantoprazole Sodium | 40 | $1,200 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $177 | $966,589146 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $586 | $203,036268 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $238 | $79,372103 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 192 pulmonary disease providers in South Carolina.
Other pulmonary disease in Myrtle Beach
- Alan CohenMyrtle Beach$12K
- Milica AnticMyrtle Beach$10K
- Abhijit RavalAnderson$2M
- Richard BoganColumbia$1.1M
- Joseph BosciaSpartanburg$701K
- Patrick FlumeCharleston$418K
- Sean CallahanGreenville$321K
- Laura HerpelColumbia$254K
- Gerard SilvestriCharleston$254K
- Arun AdlakhaRock Hill$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.